AllianceBernstein
TCRR

AllianceBernstein’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

AllianceBernstein’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-22,200
Closed -$61K – 3440
2022
Q1 		$61K Sell
22,200
-5,100
-19% -$16K ﹤0.01% 3160
2021
Q4 		$127K Hold
27,300
– – ﹤0.01% 3163
2021
Q3 		$232K Hold
27,300
– – ﹤0.01% 3046
2021
Q2 		$448K Buy
27,300
+6,600
+32% +$133K ﹤0.01% 2859
2021
Q1 		$457K Sell
20,700
-3,400
-14% -$92.7K ﹤0.01% 2696
2020
Q4 		$745K Buy
24,100
+13,100
+119% +$331K ﹤0.01% 2415
2020
Q3 		$224K Sell
11,000
-5,100
-32% -$89.5K ﹤0.01% 2932
2020
Q2 		$247K Buy
+16,100
New +$186K ﹤0.01% 2949

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

AllianceBernstein's TCRR Position: Q2 2022 in Review

AllianceBernstein sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2022, closing a stake of 22,200 shares — an estimated $61K sold.

AllianceBernstein first reported a position in TCRR in Q2 2020 and held it in 8 quarters. The position peaked at $745K in Q4 2020. 83 funds tracked by Wall St. Rank hold TCRR as of Q2 2022.

  • AllianceBernstein reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • AllianceBernstein sold 22,200 TCR2 Therapeutics Inc. Common Stock shares in Q2 2022, an estimated $61K.
  • AllianceBernstein first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2020 and held it in 8 quarters.
  • AllianceBernstein's TCR2 Therapeutics Inc. Common Stock position peaked at $745K in Q4 2020.
  • 83 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2022.

Based on AllianceBernstein's 13F filing for Q2 2022, filed 15 Aug 2022.